Dr. Silver is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
NewYork-Presbyterian/Weill Cornell Medical Center
533 East 70th Street Starr Pavilion, 3rd Floor
New York, NY 10034Phone+1 646-962-2700- Is this information wrong?
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1956 - 1958
- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1953 - 1954
- Weill Cornell MedicineClass of 1953
Certifications & Licensure
- NY State Medical License 1954 - 2025
- PA State Medical License 1983 - 1984
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Familial Myeloproliferative Disorders Start of enrollment: 2008 Mar 01
- Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Polycythemia vera: aspects of its current diagnosis and initial treatment.Richard T Silver, Ghaith Abu-Zeinah> ;Expert Review of Hematology. 2023 Apr 1
- 1 citationsSplenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival.Richard T Silver, Katie Erdos, Elwood Taylor 3rd, Joseph M Scandura, Ghaith Abu-Zeinah> ;Leukemia. 2023 Mar 1
- 4 citationsPatient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.Kathryn E Flynn, Ehab Atallah, Li Lin, Neil P Shah, Richard T Silver, Richard A Larson, Javier Panilla-Ibarz, James E Thompson, Vivian G Oehler, Jerald P Radich, Vamsi...> ;Haematologica. 2022 Nov 1
- Join now to see all
Abstracts/Posters
- Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Recombinant Interferon-_ Reduces Thrombotic Events in Patients with Polycythemia VeraRichard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
- Dave Boule Confronted Polycythemia Vera with an Accountant’s ConsistencyJune 17th, 2022
- Cancer Pill Could Keep Patients Alive for More Than 10 Years, New Study FindsMarch 10th, 2017
- 'Imatinib Changed Everything'March 8th, 2017
- Join now to see all
Hospital Affiliations
- New York-Presbyterian HospitalNew York, New York
- NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: